Oscar Health (NYSE:OSCR) Given New $27.00 Price Target at Wells Fargo & Company

Oscar Health (NYSE:OSCR) had its target price boosted by Wells Fargo & Company from $24.00 to $27.00 in a research note issued to investors on Wednesday, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

Several other equities analysts have also recently issued reports on the company. Bank of America reiterated a neutral rating and set a $21.00 price target (down from $25.00) on shares of Oscar Health in a research report on Thursday, May 30th. Robert W. Baird began coverage on Oscar Health in a research report on Thursday, May 30th. They set an outperform rating and a $28.00 price target on the stock. Raymond James began coverage on Oscar Health in a research report on Friday, March 22nd. They set an outperform rating and a $20.00 price target on the stock. Baird R W raised Oscar Health to a strong-buy rating in a research note on Thursday, May 30th. Finally, The Goldman Sachs Group raised their price objective on Oscar Health from $16.00 to $21.00 and gave the stock a neutral rating in a research note on Thursday, May 9th. Three investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $19.00.

Oscar Health Stock Down 4.7 %

OSCR opened at $19.06 on Wednesday. Oscar Health has a 12 month low of $4.72 and a 12 month high of $23.44. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.10 and a quick ratio of 1.10. The stock has a market cap of $4.52 billion, a P/E ratio of -47.65 and a beta of 1.68. The stock’s 50 day moving average price is $18.74 and its 200 day moving average price is $14.54.

Oscar Health (NYSE:OSCR) last posted its earnings results on Tuesday, May 7th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.28 by $0.34. Oscar Health had a negative return on equity of 5.77% and a negative net margin of 0.82%. The firm had revenue of $2.14 billion for the quarter, compared to analysts’ expectations of $1.99 billion. During the same period last year, the firm earned ($0.18) EPS. The firm’s revenue was up 45.8% compared to the same quarter last year. As a group, research analysts predict that Oscar Health will post -0.04 earnings per share for the current year.

Insider Transactions at Oscar Health

In other news, EVP Alessandrea C. Quane sold 25,550 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $19.46, for a total value of $497,203.00. Following the completion of the sale, the executive vice president now owns 237,347 shares of the company’s stock, valued at $4,618,772.62. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, COO Steven Wolin sold 18,607 shares of Oscar Health stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $19.46, for a total transaction of $362,092.22. Following the completion of the sale, the chief operating officer now owns 65,316 shares of the company’s stock, valued at $1,271,049.36. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Alessandrea C. Quane sold 25,550 shares of Oscar Health stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $19.46, for a total value of $497,203.00. Following the sale, the executive vice president now directly owns 237,347 shares of the company’s stock, valued at approximately $4,618,772.62. The disclosure for this sale can be found here. Insiders sold a total of 81,655 shares of company stock valued at $1,589,006 over the last quarter. Company insiders own 25.11% of the company’s stock.

Institutional Trading of Oscar Health

Institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its position in Oscar Health by 19.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,125,355 shares of the company’s stock valued at $6,268,000 after purchasing an additional 182,206 shares during the last quarter. Graham Capital Management L.P. acquired a new stake in shares of Oscar Health in the third quarter worth about $894,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Oscar Health by 270.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 265,031 shares of the company’s stock worth $2,425,000 after buying an additional 193,512 shares during the last quarter. Dark Forest Capital Management LP acquired a new stake in shares of Oscar Health in the third quarter worth about $581,000. Finally, National Bank of Canada FI acquired a new stake in shares of Oscar Health in the fourth quarter worth about $1,071,000. Institutional investors and hedge funds own 75.70% of the company’s stock.

Oscar Health Company Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.